Clinical study on patient-derived organoids as a predictive model for assessing treatment response in pancreatic cancer
10.3760/cma.j.cn113855-20230502-00217
- VernacularTitle:患者源性类器官作为评估胰腺癌治疗反应预测模型的临床研究
- Author:
Suya SHEN
1
;
Jingjing LI
;
Hao CHENG
;
Wenyan GUAN
;
Zhiwen LI
;
Xiao FU
;
Yingzhe HU
;
Zhenghua CAI
;
Yuqing HAN
;
Yudong QIU
Author Information
1. 南京大学医学院附属鼓楼医院胰腺外科，南京 210008
- Keywords:
Pancreatic neoplasms;
Organoids;
Adjuvant therapy;
Prognosis
- From:
Chinese Journal of General Surgery
2023;38(9):655-661
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To construct a biospecimen bank of patient derived organoids (PDOs) from pancreatic cancer tissues and to explore the feasibility of PDOs drug sensitivity assay technology to guide chemotherapy drug selection for pancreatic cancer.Methods:Pancreatic cancer tissue specimens obtained after surgical resection and puncture biopsy from Mar 2020 to Dec 2022 at Drum Tower Hospital, Nanjing University School of Medicine were collected. Pancreatic cancer PDOs were cultured in vitro and histologically identified; PDOs were treated with gemcitabine, Nab-paclitaxel, fluorouracil, Oxaliplatin, and Irinotecan and cell viability was measured to analyze the correlation between PDOs drug sensitivity and the actual clinical treatment response.Results:The PDOs can reproduce the pathological features of corresponding tumor tissues; the sensitivity of different PDOs to the same chemotherapeutic drug is significantly different; The sensitivity of PDOs was highly consistent with the actual treatment effect of the corresponding patients 75.76% (25/33); organoid organ-based susceptibility testing had predictive value for the treatment response of patients (AUC=0.733, 95% CI: 0.546-0.919, P<0.05). Conclusion:A biobank of pancreatic cancer PDOs was successfully constructed, and the drug susceptibility test results were significantly correlated with the actual medication response of patients, suggesting that the drug susceptibility test technology based on PDOs has the potential to guide individualized chemotherapy for pancreatic cancer.
